Support the development and delivery of HEOR strategies and evidence-generation activities across hematology assets in Europe and New Markets. Partner with Market Access, Medical Affairs, Clinical Development, Biostatistics and Global teams to identify evidence gaps and prioritize HEOR activities based on regional and country needs. Develop and execute evidence-generation projects, including comparative effectiveness research, real-world evidence and health economic analyses. Contribute to European HTA and EU Joint Clinical Assessment (JCA) evidence strategy and readiness. Support JCA PICO strategy and planning, including assessment of relevant populations, subgroups, comparators and outcomes, identification of evidence gaps and evaluation of potential evidence-generation approaches. Lead or support comparative evidence generation for JCA and other HTA requirements. Develop and critically review study protocols, analysis plans, reports, publications and other HEOR deliverables, ensuring scientific and methodological quality. Evaluate clinical trial, external and real-world data together with internal experts and external partners to determine the most appropriate approaches for addressing evidence gaps. Manage external HEOR vendors and projects, including scope definition, methodological review, timelines, deliverables and quality control. Support the interpretation and communication of HEOR evidence, including assumptions, uncertainty, limitations and implications for HTA and evidence strategy.
Our client is a global, science-led biopharmaceutical company focused on oncology, with a strong international footprint and a commitment to accelerating the development of and access to innovative cancer medicines. With hematology as a core area of research and development, the organization combines global capabilities with a fast-moving, collaborative culture and a strong focus on generating meaningful impact for patients.
